[{"id":"e7bd79ed-e1db-4e9b-bb76-4a8a179e7ded","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913804","created_at":"2023-06-22T19:11:41.291Z","updated_at":"2024-07-02T16:35:45.048Z","phase":"Phase 1","brief_title":"YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05913804","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/15/2023","start_date":" 06/15/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-06-22"},{"id":"893364f9-94b4-4ba6-a42f-b2399b5cc9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05739409","created_at":"2023-05-17T22:04:44.533Z","updated_at":"2024-07-02T16:35:55.011Z","phase":"","brief_title":"LILRB4 STAR-T Cell Therapy for Monocytic Leukemia","source_id_and_acronym":"NCT05739409","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-02-22"},{"id":"e88da068-9605-4405-b63c-5767e31d20f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05518357","created_at":"2023-05-17T22:04:43.826Z","updated_at":"2024-07-02T16:35:57.735Z","phase":"Phase 1","brief_title":"LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05518357","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2023-01-12"},{"id":"de59778c-3ed1-4ae8-9ba9-f43ec335a40c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05548088","created_at":"2023-05-17T22:04:44.026Z","updated_at":"2024-07-02T16:36:03.673Z","phase":"Phase 1","brief_title":"LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05548088","lead_sponsor":"Peking University People's Hospital","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • YTS104"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2022-09-21"}]